

AMENDMENTS TO THE CLAIMS

1-12. (Cancelled)

13. (Currently amended) A method of promoting corneal neuritogenesis, which comprises administering an effective amount of a Rho protein inhibitor Exoenzyme C3 or a Rho kinase inhibitor (ROCK inhibitor) to a subject in need of the promotion of the corneal neuritogenesis.

14. (Withdrawn - currently amended) A method of promoting extension of corneal nerve axon, which comprises administering an effective amount of a Rho protein inhibitor Exoenzyme C3 or a ROCK inhibitor to a subject in need of the promotion of extension of the corneal nerve axon.

15. (Withdrawn - currently amended) A method of recovering corneal sensitivity, which comprises administering an effective amount of a Rho protein inhibitor Exoenzyme C3 or a ROCK inhibitor to a subject in need of the recovery of corneal sensitivity.

16. (Withdrawn - currently amended) A method of treating dry eye, which comprises administering an effective amount of a Rho protein inhibitor Exoenzyme C3 or a ROCK inhibitor to a subject affected with dry eye.

17. (New) The method according to claim 13, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.

18. (New) The method according to claim 14, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.

19. (New) The method according to claim 15, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.

20. (New) The method according to claim 16, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.